TMS denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies TMS as Experimental — and How to Appeal

Aetna's "experimental or investigational" denial classification is applied when the insurer determines that the evidence base for a treatment does not yet meet its internal threshold for established medical practice. For transcranial magnetic stimulation (TMS), this denial is most commonly issued for indications beyond the FDA-cleared uses — for example, when TMS is prescribed for an anxiety disorder, OCD, PTSD, chronic pain, or another condition for which the FDA has not granted clearance for TMS devices, or for which Aetna's Clinical Policy Bulletin has not yet been updated to reflect current evidence. Even when TMS is FDA-cleared for your specific diagnosis, Aetna may still apply an experimental classification based on specific protocol variations.

## Why This Denial Is Appealable

The experimental classification is contestable when: (a) TMS has FDA clearance for your specific diagnosis and protocol, (b) the relevant specialty guidelines (e.g., from the applicable American Psychiatric Association or similar body) recognize TMS as an established treatment option, or (c) the peer-reviewed literature and standard clinical practice at major academic medical centers support TMS for your condition. Your clinician's letter citing the guideline organization and describing the published evidence base — without fabricating specific statistics — is the key document.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Aetna must decide within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): Experimental denials are among the most commonly reversed at external review. After exhausting internal review, you have approximately four months to request independent external review. External reviewers apply objective medical evidence standards, not the insurer's internal policy thresholds.
• Expedited review: Available when standard timelines would endanger your health.

## Documentation to Gather

1. FDA clearance documentation: Print the relevant FDA 510(k) clearance or De Novo authorization for TMS for your specific indication — this is public record at fda.gov. It directly undercuts the experimental label if your diagnosis falls within the cleared indication. 2. Diagnosis and severity records: Treating provider records confirming diagnosis and clinical severity. 3. Treating clinician letter: A detailed letter explaining why TMS is the appropriate treatment, referencing the relevant guideline organization and characterizing the evidence as established — without citing specific trial names or percentages. 4. Prior-treatment failure history: Documentation of treatments tried before TMS was recommended, with dates and outcomes. 5. Peer-reviewed literature summary: Ask your clinician to attach one or two published systematic review citations (journal, year, conclusion summary — no fabricated statistics) if they are prepared to stand behind the citations.

## Criteria-Mapping Structure

Locate Aetna's Clinical Policy Bulletin for TMS on Aetna.com and identify every criterion under the "experimental" classification. For each one, document the specific FDA status, guideline reference, and chart evidence that distinguishes your case from the experimental category. Make the FDA clearance document the first exhibit — it is your strongest rebuttal to this denial type.